EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro and in vivo characterization of wild type BMP9 and a non-osteogenic variant in models of pulmonary arterial hypertension

Tobias G Schips iD, Karl W Kavalkovich, Lai-Ming Yung, Salam Ibrahim, Makhosi Edmondson, Zhigang Hong, Chin-Hu Huang, Simon Hinke iD, Xinkang Wang, Andrea R Nawrocki, Annmarie Winkis, Jinquan Luo und 6 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0329089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Tobias G Schips und 17 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research & Development, LLC, Spring House, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Growth Differentiation Factor 2, Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endothelial dysfunction and the resulting vascular remodeling are hallmarks of pulmonary hypertension, a debilitating disease of high arterial pressure in the lungs and the right side of the heart. Mutations in the BMPR2 signaling pathway are associated with the development of pulmonary arterial hypertension. Previous pre-clinical studies demonstrated that exogenous administration of recombinant human wild type BMP9 (WT BMP9) enhances BMPR2/ALK1 mediated signaling and reverses experimental pulmonary hypertension in rat models. However, BMP9 induces osteogenic activity in progenitor cells through activation of ActR2A and ActR2B receptor complexes potentially leading to unwanted bone formation in non-osteogenic tissues. The cellular activity of human WT BMP9 and amino acid substitution variants was characterized in vitro in terms of BMPR2 and ActR2 signaling. We identified a mutant variant of human BMP9 that maintains its activity in endothelial cells, specifically preserving BMPR2 signaling while eliminating osteogenic signaling associated with ActR2A/B activation in mesenchymal precursor cells. Rat models of pulmonary hypertension served as in vivo models to characterize efficacy and safety of BMP9 supplementation therapy. While WT BMP9 effectively activates BMPR2 signaling across species in rat, cynomolgus monkey and human systems, our human BMP9 mutant variant is inactive on rat BMPR2/ALK1 receptor complexes. Therefore, WT BMP9 was used to examine disease reversal in the preclinical monocrotaline model rat of pulmonary hypertension. WT BMP9 failed to improve right ventricular systolic pressure or right ventricular hypertrophy, despite clear target engagement shown by upregulation of SMAD7. Telemetry studies of WT BMP9 in the Sugen 5416 and hypoxia rat model of pulmonary hypertension indicated no significant change in pulmonary pressure but led to increased systemic blood pressure and decreased heart rate. Additionally, escalating doses in naive rats caused severe dose-limiting effects and morbidity at 500 µg/kg/day or higher. Given these findings including the absence of therapeutic efficacy in a relevant PAH animal model and dose limiting toxicity in rats, a therapeutic window for BMP9 treatment could not be established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Growth Differentiation Factor 2Pulmonary Arterial HypertensionHypertension, PulmonaryAnimalsHumansBone Morphogenetic Protein Receptors, Type IIRatsDisease Models, AnimalSignal TransductionMaleOsteogenesisRats, Sprague-Dawley

Substanzen

Growth Differentiation Factor 2Bone Morphogenetic Protein Receptors, Type IIGDF2 protein, humanBMPR2 protein, human

Autor:innen und Institutionen

  • Janssen Research & Development, LLC, Spring House, Pennsylvania, United States of America.

ORCID-Profile: Tobias G Schips, Simon Hinke, Russell Bialecki

Förderung

  • Janssen Research and Development

Zitieren

APA

Schips, T. G., Kavalkovich, K. W., Yung, L. M., Ibrahim, S., Edmondson, M., Hong, Z., Huang, C. H., Hinke, S., Wang, X., Nawrocki, A. R., Winkis, A., Luo, J., Farasat, I., Geist, B., Wang, Y., Bialecki, R., Jeyaseelan, J. R., & Bauman, D. R. (2025). In vitro and in vivo characterization of wild type BMP9 and a non-osteogenic variant in models of pulmonary arterial hypertension. PLOS One. https://doi.org/10.1371/journal.pone.0329089

Vancouver

Schips TG, Kavalkovich KW, Yung LM, Ibrahim S, Edmondson M, Hong Z, et al. In vitro and in vivo characterization of wild type BMP9 and a non-osteogenic variant in models of pulmonary arterial hypertension. PLOS One. 2025. doi:10.1371/journal.pone.0329089

BibTeX
@article{Schips2025,
  author = {Schips, Tobias G and Kavalkovich, Karl W and Yung, Lai-Ming and Ibrahim, Salam and Edmondson, Makhosi and Hong, Zhigang and Huang, Chin-Hu and Hinke, Simon and Wang, Xinkang and Nawrocki, Andrea R and Winkis, Annmarie and Luo, Jinquan and Farasat, Iman and Geist, Brian and Wang, Yang and Bialecki, Russell and Jeyaseelan, Jey R and Bauman, David R},
  title = {In vitro and in vivo characterization of wild type BMP9 and a non-osteogenic variant in models of pulmonary arterial hypertension},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0329089}
}
Kostenlos starten →